NCT03878849 2025-08-28
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Allarity Therapeutics
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07120451 2025-08-13
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
Fudan University
Phase 2 Not yet recruiting
NCT07059676 2025-07-11
LIBINI-1
Clinica Universidad de Navarra, Universidad de Navarra
Not yet recruiting
NCT05775549 2024-09-20
FLAME
AstraZeneca
Completed
NCT06542549 2024-08-07
Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer
Anhui Provincial Hospital
Phase 3 Not yet recruiting
NCT04065009 2024-01-11
IPLA-OVCA
Karolinska Institutet
Phase 3 Active not recruiting
NCT05794659 2023-07-20
Cornerstone4
Aston Sci. Inc.
Phase 2 Not yet recruiting
NCT04360629 2022-06-01
Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer
Fudan University
Phase NA Completed
NCT04556539 2021-05-12
Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 2 Unknown
NCT01989546 2021-02-23
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04135521 2020-06-29
Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
Far Eastern Memorial Hospital
Completed
NCT03611179 2018-08-02
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
Assiut University
Phase 2 Unknown